MUMBAI, India, July 6, 2026
Lupin Limited, one of the world’s leading pharmaceutical companies, has been recognized among TIME and Statista’s World’s Most Sustainable Companies 2026, highlighting the company’s continued commitment to environmental stewardship, responsible business practices, strong corporate governance, and positive social impact. Making its debut on the prestigious global ranking, Lupin secured the 318th position among 750 companies, selected from more than 5,000 of the world’s largest and most influential organizations. The recognition reflects Lupin’s sustained efforts to integrate Environmental, Social, and Governance (ESG) principles across its global pharmaceutical operations while creating long-term value for patients, healthcare systems, employees, investors, and communities. As one of only 16 Indian companies included in this year’s ranking, Lupin continues to strengthen its reputation as a global pharmaceutical leader committed to advancing sustainable healthcare through responsible manufacturing, climate action, and transparent governance while supporting innovation across branded medicines, generics, biotechnology, and active pharmaceutical ingredients.
Global Sustainability Recognition Highlights Lupin’s ESG Leadership
The TIME and Statista World’s Most Sustainable Companies 2026 ranking evaluated organizations using more than 20 comprehensive sustainability indicators, assessing performance across environmental responsibility, governance standards, reporting transparency, sustainability commitments, and social impact initiatives. Lupin’s inclusion reflects years of strategic investment in integrating ESG principles throughout its worldwide operations. The company has consistently focused on reducing its environmental footprint through renewable energy adoption, climate transition initiatives, resource conservation, and responsible water management, while strengthening corporate governance frameworks and enhancing transparency across its business activities.
Company leadership emphasized that sustainability remains central to Lupin’s long-term business strategy, supporting operational excellence while delivering innovative healthcare solutions responsibly. The recognition also validates the company’s commitment to embedding sustainability into decision-making processes across manufacturing, research, supply chain management, and global business operations, reinforcing its vision of creating lasting value for patients and society.
Strong ESG Performance Reinforces Responsible Pharmaceutical Manufacturing
Advertisement
Lupin’s latest recognition builds upon an impressive record of global ESG achievements that position the company among the pharmaceutical industry’s sustainability leaders. The company previously received CDP’s highest ‘A’ Leadership Rating for both Climate Change and Water Security, demonstrating excellence in environmental performance and climate risk management. In addition, Lupin achieved an outstanding S&P Global Corporate Sustainability Assessment (CSA) score of 91 in 2025, reflecting strong performance across governance, environmental management, ethics, risk oversight, and stakeholder engagement.
These achievements demonstrate the company’s commitment to responsible pharmaceutical manufacturing while supporting global efforts to reduce greenhouse gas emissions, improve operational efficiency, strengthen environmental resilience, and promote sustainable resource utilization. Through continued investment in cleaner technologies, renewable energy infrastructure, and ESG-focused business strategies, Lupin continues to align its operations with evolving global sustainability expectations while maintaining high standards of quality, compliance, and patient care.
Sustainability Supports Lupin’s Long-Term Global Healthcare Strategy
As a global pharmaceutical company operating in more than 100 countries, Lupin continues to integrate sustainability into every aspect of its business, from drug development and manufacturing to research, digital health, diagnostics, and active pharmaceutical ingredient production. With 15 advanced manufacturing facilities, seven research centers, and a workforce of more than 24,000 professionals, the company remains focused on improving healthcare outcomes while minimizing environmental impact and strengthening corporate responsibility.
Lupin’s expanding portfolio spans branded medicines, complex generics, biotechnology products, active pharmaceutical ingredients, diagnostics, digital health solutions, and manufacturing services, supporting patients across multiple therapeutic areas worldwide. The recognition by TIME and Statista reinforces Lupin’s position as a pharmaceutical company successfully combining scientific innovation, responsible manufacturing, strong governance, and sustainable business practices. As ESG considerations continue to influence global healthcare and pharmaceutical industries, Lupin’s commitment to sustainability positions the company for long-term growth while contributing to a more resilient, transparent, and environmentally responsible future for global healthcare.
Source: Lupin press release
